BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Parkinson's Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Parkinson's Disease\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06773962-1727@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261128
DTEND;VALUE=DATE:20261129
SUMMARY:TB006: Phase 2 readout est. (NCT06773962)
DESCRIPTION:TB006\, phase 2\, Parkinson's Disease.\nStudy: A Phase 2a Multi
 center Clinical Trial of TB006 in Participants With Parkinson's Disease\nE
 stimated primary completion: 28 November 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tb006#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06773962
URL:https://assetmemo.bio/drug/tb006#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07142044-8731@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:EC5026: Phase 1/2 readout est. (NCT07142044)
DESCRIPTION:EC5026\, phase 1/2\, Parkinson's Disease.\nStudy: Safety\, Tole
 rability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP S
 tudy)\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ec5026#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07142044
URL:https://assetmemo.bio/drug/ec5026#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07028632-1742@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:NouvNeu001: Phase 2 readout est. (NCT07028632)
DESCRIPTION:NouvNeu001\, phase 2\, Parkinson's Disease.\nStudy: The Safety\
 , Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease\nEstimate
 d primary completion: December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nouvneu001#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07028632
URL:https://assetmemo.bio/drug/nouvneu001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005180-1654@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HBI-002: Phase 2 readout est. (NCT07005180)
DESCRIPTION:HBI-002\, phase 2\, Parkinson's Disease.\nStudy: Low-dose Carbo
 n Monoxide (HBI-002) Trial to Evaluate Safety\, Tolerability\, PK\, and Bi
 omarkers in Parkinson's Disease\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/hbi-002#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07005180
URL:https://assetmemo.bio/drug/hbi-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06602193-1609@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:BIIB122 / DNL151 (LRRK2 inhibitor): Phase 2 readout est. (NCT066021
 93)
DESCRIPTION:BIIB122 / DNL151 (LRRK2 inhibitor)\, phase 2\, Parkinson's Dise
 ase.\nStudy: Safety and Pharmacodynamic Effects of BIIB122 in Participants
  With LRRK2-Associated Parkinson's Disease (LRRK2-PD)\nEstimated primary c
 ompletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/biib122-dnl151-lrrk2-inhibitor#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06602193
URL:https://assetmemo.bio/drug/biib122-dnl151-lrrk2-inhibitor#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07461220-1659@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Linepemat (IRL757): Phase 1/2 readout est. (NCT07461220)
DESCRIPTION:Linepemat (IRL757)\, phase 1/2\, Parkinson's Disease.\nStudy: S
 afety and Tolerability of IRL757 in Participants With Parkinson's Disease 
 and Apathy\nEstimated primary completion: May 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/linepemat-irl757#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07461220
URL:https://assetmemo.bio/drug/linepemat-irl757#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322887-1639@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:SUL-238: Phase 2 readout est. (NCT07322887)
DESCRIPTION:SUL-238\, phase 2\, Parkinson's Disease.\nStudy: A Phase 2 Stud
 y to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MR
 S in Patients With Early\, Untreated Parkinson's Disease\nEstimated primar
 y completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/sul-238#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07322887
URL:https://assetmemo.bio/drug/sul-238#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07080775-1737@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:XS-411: Phase 1/2 readout est. (NCT07080775)
DESCRIPTION:XS-411\, phase 1/2\, Parkinson's Disease.\nStudy: The Safety\,T
 olerability\, Efficacy of XS411 Cell Injection for the Treatment of Primar
 y Parkinson's Disease\nEstimated primary completion: July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/xs-411#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07080775
URL:https://assetmemo.bio/drug/xs-411#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976268-1604@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:BHV-8000: Phase 2/3 readout est. (NCT06976268)
DESCRIPTION:BHV-8000\, phase 2/3\, Parkinson's Disease.\nStudy: A Study to 
 Determine if BHV-8000 is Effective\, Safe and Tolerable as a Treatment for
  Adults Living With Early Parkinson's Disease\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bhv-8
 000#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06976268
URL:https://assetmemo.bio/drug/bhv-8000#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106021-1668@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:RNDP-001: Phase 1/2 readout est. (NCT07106021)
DESCRIPTION:RNDP-001\, phase 1/2\, Parkinson's Disease.\nStudy: A Study to 
 Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients Wit
 h Idiopathic Parkinson's Disease\nEstimated primary completion: September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rndp-001#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07106021
URL:https://assetmemo.bio/drug/rndp-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102342-1742@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:NouvNeu001: Phase 1/2 readout est. (NCT07102342)
DESCRIPTION:NouvNeu001\, phase 1/2\, Parkinson's Disease.\nStudy: This Clin
 ical Trial is Designed to Evaluate the Safety\, Tolerability\, Feasibility
  and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cel
 ls Injection) in Patients With Parkinson's Disease.\nEstimated primary com
 pletion: September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nouvneu001#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07102342
URL:https://assetmemo.bio/drug/nouvneu001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07414290-1718@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:VGN-R08b: Phase 1/2 readout est. (NCT07414290)
DESCRIPTION:VGN-R08b\, phase 1/2\, Parkinson's Disease.\nStudy: A Trial to 
 Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Di
 sease Patients With GBA1 Mutations\nEstimated primary completion: 1 Septem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vgn-r08b#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074142
 90
URL:https://assetmemo.bio/drug/vgn-r08b#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432958-1574@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270903
DTEND;VALUE=DATE:20270904
SUMMARY:AP-472: Phase 2 readout est. (NCT07432958)
DESCRIPTION:AP-472\, phase 2\, Parkinson's Disease.\nStudy: A Study to Eval
 uate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Lev
 odopa in Parkinson's Disease (PD) Participants With Motor Fluctuations\nEs
 timated primary completion: 3 September 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ap-472#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07432958
URL:https://assetmemo.bio/drug/ap-472#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07725562-1735@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:VG081821AC: Phase 2/3 readout est. (NCT07725562)
DESCRIPTION:VG081821AC\, phase 2/3\, Parkinson's Disease.\nStudy: VG081821A
 C Tablets for Early to Mid-stage Parkinson's Disease\nEstimated primary co
 mpletion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/vg081821ac#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07725562
URL:https://assetmemo.bio/drug/vg081821ac#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06431971-1663@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Talineuren: Phase 2 readout est. (NCT06431971)
DESCRIPTION:Talineuren\, phase 2\, Parkinson's Disease.\nStudy: Estimates o
 f the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson 
 Disease\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/talineuren#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06431971
URL:https://assetmemo.bio/drug/talineuren#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680830-1691@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:NEU-411: Phase 2 readout est. (NCT06680830)
DESCRIPTION:NEU-411\, phase 2\, Parkinson's Disease.\nStudy: A Phase 2 Stud
 y and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Par
 ticipants With Early Parkinson's Disease\nEstimated primary completion: De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/neu-411#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0668
 0830
URL:https://assetmemo.bio/drug/neu-411#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07761936-1777@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Xadago (Safinamide): Phase 3 readout est. (NCT07761936)
DESCRIPTION:Xadago (Safinamide)\, phase 3\, Parkinson's Disease.\nStudy: Sa
 finamide vs Placebo for Pain in Patients With Parkinson's Disease and Moto
 r Fluctuations\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/safinamide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07761936
URL:https://assetmemo.bio/drug/safinamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06175767-1684@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:MT101-5: Phase 2 readout est. (NCT06175767)
DESCRIPTION:MT101-5\, phase 2\, Parkinson's Disease.\nStudy: A Study to Eva
 luate the Safety\, Tolerability and Efficacy of MT101-5 in Subjects With E
 arly Parkinson's Disease\nEstimated primary completion: January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/mt101-5#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06175767
URL:https://assetmemo.bio/drug/mt101-5#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07166757-1737@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:XS-411: Phase 1/2 readout est. (NCT07166757)
DESCRIPTION:XS-411\, phase 1/2\, Parkinson's Disease.\nStudy: Clinical Stud
 y to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease\nEstim
 ated primary completion: 30 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/xs-411#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07166757
URL:https://assetmemo.bio/drug/xs-411#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215403-1583@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ametefgene parvec: Phase 2 readout est. (NCT07215403)
DESCRIPTION:Ametefgene parvec\, phase 2\, Parkinson's Disease.\nStudy: Open
 -Label\, Multi-Stage Study to Optimize the Intraputaminal Administration o
 f AB-1005 Using a Prescriptive Infusion Algorithm (PIA)\nEstimated primary
  completion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ametefgene-parvec#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07215403
URL:https://assetmemo.bio/drug/ametefgene-parvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06015841-1567@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:AFFITOPE PD01A / ACI-7104.056: Phase 2 readout est. (NCT06015841)
DESCRIPTION:AFFITOPE PD01A / ACI-7104.056\, phase 2\, Parkinson's Disease.\
 nStudy: A Study to Evaluate the Effects of ACI-7104.056 in Patients With E
 arly Stages of Parkinson's Disease\nEstimated primary completion: June 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/affitope-pd01a-aci
 -7104-056#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06015841
URL:https://assetmemo.bio/drug/affitope-pd01a-aci-7104-056#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07280299-1640@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:GT-02287: Phase 2 readout est. (NCT07280299)
DESCRIPTION:GT-02287\, phase 2\, Parkinson's Disease.\nStudy: Efficacy\, Sa
 fety\, Tolerability\, and Biomarker Effects of GT-02287 in Early Parkinson
 's Disease\nEstimated primary completion: 30 June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/gt-02287#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07280299
URL:https://assetmemo.bio/drug/gt-02287#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06285643-1583@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ametefgene parvec: Phase 2 readout est. (NCT06285643)
DESCRIPTION:Ametefgene parvec\, phase 2\, Parkinson's Disease.\nStudy: A St
 udy of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-P
 D)\nEstimated primary completion: 31 August 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ametefgene-parvec#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06285643
URL:https://assetmemo.bio/drug/ametefgene-parvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944522-1768@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Bemdaneprocel (MSK-DA01): Phase 3 readout est. (NCT06944522)
DESCRIPTION:Bemdaneprocel (MSK-DA01)\, phase 3\, Parkinson's Disease.\nStud
 y: A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adul
 ts Who Have Parkinson's Disease\nEstimated primary completion: October 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bemdaneprocel-msk-
 da01#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06944522
URL:https://assetmemo.bio/drug/bemdaneprocel-msk-da01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514858-1646@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20281003
DTEND;VALUE=DATE:20281004
SUMMARY:Lu AF28996: Phase 2 readout est. (NCT07514858)
DESCRIPTION:Lu AF28996\, phase 2\, Parkinson's Disease.\nStudy: A Trial Inv
 estigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fl
 uctuations\nEstimated primary completion: 3 October 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lu-af28996#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07514858
URL:https://assetmemo.bio/drug/lu-af28996#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05778617-1568@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Ambroxol: Phase 3 readout est. (NCT05778617)
DESCRIPTION:Ambroxol\, phase 3\, Parkinson's Disease.\nStudy: Ambroxol to S
 low Progression in Parkinson Disease\nEstimated primary completion: Februa
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ambroxol#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0577861
 7
URL:https://assetmemo.bio/drug/ambroxol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566429-1583@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290615
DTEND;VALUE=DATE:20290616
SUMMARY:Ametefgene parvec: Phase 2 readout est. (NCT07566429)
DESCRIPTION:Ametefgene parvec\, phase 2\, Parkinson's Disease.\nStudy: A St
 udy of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's D
 isease (J-REGENERATE-PD)\nEstimated primary completion: 15 June 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ametefgene-parvec#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07566429
URL:https://assetmemo.bio/drug/ametefgene-parvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174310-1655@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Prasinezumab: Phase 3 readout est. (NCT07174310)
DESCRIPTION:Prasinezumab\, phase 3\, Parkinson's Disease.\nStudy: A Study t
 o Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Par
 ticipants With Early-Stage Parkinson's Disease\nEstimated primary completi
 on: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pra
 sinezumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07174310
URL:https://assetmemo.bio/drug/prasinezumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733349-8723@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:UX-DA003: Phase 1/2 readout est. (NCT07733349)
DESCRIPTION:UX-DA003\, phase 1/2\, Parkinson's Disease.\nStudy: Phase I/II 
 Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Pa
 rkinson's Disease\nEstimated primary completion: 31 August 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ux-da003#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07733349
URL:https://assetmemo.bio/drug/ux-da003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284784-738@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Buntanetap: Phase 2/3 readout est. (NCT07284784)
DESCRIPTION:Buntanetap\, phase 2/3\, Parkinson's Disease.\nStudy: A Study o
 f Buntanetap in Participants With PD\nEstimated primary completion: Septem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/buntanetap#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0728
 4784
URL:https://assetmemo.bio/drug/buntanetap#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05894343-8717@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:AAV-GAD gene therapy: Phase 1/2 readout est. (NCT05894343)
DESCRIPTION:AAV-GAD gene therapy\, phase 1/2\, Parkinson's Disease.\nStudy:
  Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in
  Parkinson's Disease\nEstimated primary completion: October 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/aav-gad-gene-therapy#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05894343
URL:https://assetmemo.bio/drug/aav-gad-gene-therapy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647614-1637@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:ENERGI-F705: Phase 2 readout est. (NCT07647614)
DESCRIPTION:ENERGI-F705\, phase 2\, Parkinson's Disease.\nStudy: A Study to
  Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's D
 isease\nEstimated primary completion: 1 January 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/energi-f705#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07647614
URL:https://assetmemo.bio/drug/energi-f705#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151378-1675@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20300922
DTEND;VALUE=DATE:20300923
SUMMARY:Lecigon (Trigel): Phase 3 readout est. (NCT07151378)
DESCRIPTION:Lecigon (Trigel)\, phase 3\, Parkinson's Disease.\nStudy: Intes
 tinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic
  Desensitization and Neuropsychiatric Complications in Parkinson's Disease
 \nEstimated primary completion: 22 September 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/trigel#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07151378
URL:https://assetmemo.bio/drug/trigel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07055087-1655@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Prasinezumab: Phase 2 readout est. (NCT07055087)
DESCRIPTION:Prasinezumab\, phase 2\, Parkinson's Disease.\nStudy: Prevent C
 ognitive Decline in GBA-associated Parkinson's Disease\nEstimated primary 
 completion: December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/prasinezumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07055087
URL:https://assetmemo.bio/drug/prasinezumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06753331-8718@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20301215
DTEND;VALUE=DATE:20301216
SUMMARY:Raguneprocel (Amchepry): Phase 1/2 readout est. (NCT06753331)
DESCRIPTION:Raguneprocel (Amchepry)\, phase 1/2\, Parkinson's Disease.\nStu
 dy: A Multicenter Study to Evaluate Safety\, Tolerability\, and Clinical R
 esponses of DSP-1083 Into Subjects With Parkinson's Disease\nEstimated pri
 mary completion: 15 December 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/raguneprocel-amchepry#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06753331
URL:https://assetmemo.bio/drug/raguneprocel-amchepry#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04127578-1699@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:PR001 (LY3884961): Phase 1/2 readout est. (NCT04127578)
DESCRIPTION:PR001 (LY3884961)\, phase 1/2\, Parkinson's Disease.\nStudy: Ph
 ase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's 
 Disease With at Least One GBA1 Mutation (PROPEL)\nEstimated primary comple
 tion: 31 August 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pr001-ly3884961#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04127578
URL:https://assetmemo.bio/drug/pr001-ly3884961#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
